Arginase: An old enzyme with new tricks

Trends in Pharmacological Sciences

Volumn 36, Issue 6, 2015, Pages 395-405

  Caldwell, Ruth B ^a,b   Toque, Haroldo A ^b   Narayanan, S Priya ^b,c   Caldwell, R William ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c AUGUSTA UNIVERSITY   (United States)

Author keywords

Arginase; Neurodegeneration; Nitric oxide; Oxidative stress; Peroxynitrite; Polyamine; Superoxide; Vascular dysfunction

Indexed keywords

ARGINASE; ARGINASE INHIBITOR; ENZYME INHIBITOR; NITRIC OXIDE SYNTHASE; ORNITHINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; AGING; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; MULTIPLE SCLEROSIS; NEUROTOXICITY; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REPERFUSION INJURY; RETINA INJURY; SENESCENCE; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; METABOLISM; NEUROLOGIC DISEASE; OXIDATIVE STRESS;

ANIMALS; ARGINASE; CARDIOVASCULAR DISEASES; HUMANS; NERVOUS SYSTEM DISEASES; OXIDATIVE STRESS;

EID: 84934942009     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.03.006     Document Type: Review

References (130)

1. Dzik, J.M. (2014) Evolutionary roots of arginase expression and regulation. Front. Immunol. 5, 544
2. Dizikes, G.J. et al. (1986) Isolation of human liver arginase cDNA and demonstration of nonhomology between the two human arginase genes. Biochem. Biophys. Res. Commun. 141, 53-59
3. Gotoh, T. et al. (1996) Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett. 395, 119-122
4. Vockley, J.G. et al. (1996) Cloning and characterization of the human type II arginase gene. Genomics 38, 118-123
5. Ash, D.E. (2004) Structure and function of arginases. J. Nutr. 134, 2760S-2764S discussion 2765S-2767S
6. Wu, G. and Morris, S.M., Jr (1998) Arginine metabolism: nitric oxide and beyond. Biochem. J. 336 (Pt 1), 1-17
7. Pegg, A.E. (2014) The function of spermine. IUBMB Life 66, 8-18
8. Morris, S.M., Jr (2009) Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol. 157, 922-930
9. Lucas, R. et al. (2014) Arginase in the vascular endothelium: friend or foe? Front. Immunol. 5, 589
10. Popovic, P.J. et al. (2007) Arginine and immunity. J. Nutr. 137, 1681S-1686S
11. Lee, J. et al. (2003) Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc. Natl. Acad. Sci. U.S.A. 100, 4843-4848
12. Romero, M.J. et al. (2008) Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ. Res. 102, 95-102
13. White, A.R. et al. (2006) Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 47, 245-251
14. Katusic, Z.S. et al. (2009) Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol. Sci. 30, 48-54
15. Koshland, D.E., Jr (1992) The molecule of the year. Science 258, 1861
16. Toque, H.A. and Caldwell, R.W. (2014) New approaches to the design and discovery of therapies to prevent erectile dysfunction. Expert Opin. Drug Discov. 9, 1447-1469
17. Cho, W.K. et al. (2013) IL-13 receptor alpha2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 304, L112-L124
18. Chen, B. et al. (2009) Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L1151-L1159
19. Jin, Y. et al. (2010) Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. Am. J. Physiol. Heart Circ. Physiol. 298, H1518-H1528
20. Xu, W. et al. (2004) Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 18, 1746-1748
21. Watts, J.A. et al. (2012) Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism. Pulm. Pharmacol. Ther. 25, 48-54
22. Pieper, G.M. and Dondlinger, L.A. (1997) Plasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J. Pharmacol. Exp. Ther. 283, 684-691
23. Hagenfeldt, L. et al. (1989) Plasma amino acids in relation to metabolic control in insulin-dependent diabetic children. Acta Paediatr. Scand. 78, 278-282
24. Romero, M.J. et al. (2012) Diabetes-induced vascular dysfunction involves arginase I. Am. J. Physiol. Heart Circ. Physiol. 302, H159-H166
25. Tawfik, H.E. et al. (2006) Simvastatin improves diabetes-induced coronary endothelial dysfunction. J. Pharmacol. Exp. Ther. 319, 386-395
26. Elms, S.C. et al. (2013) The role of arginase I in diabetes-induced retinal vascular dysfunction in mouse and rat models of diabetes. Diabetologia 56, 654-662
27. Bagi, Z. et al. (2013) Selective up-regulation of arginase-1 in coronary arteries of diabetic patients. Front. Immunol. 4, 293
28. Beleznai, T. et al. (2011) Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am. J. Physiol. Heart Circ. Physiol. 300, H777-H783
29. Gronros, J. et al. (2011) Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 300, H1174-H1181
30. Shemyakin, A. et al. (2012) Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 126, 2943-2950
31. Ryoo, S. et al. (2006) Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ. Res. 99, 951-960
32. Ming, X.F. et al. (2004) Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110, 3708-3714
33. Ryoo, S. et al. (2011) OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis 214, 279-287
34. Pandey, D. et al. (2014) OxLDL triggers retrograde translocation of arginase2 in aortic endothelial cells via ROCK and mitochondrial processing peptidase. Circ. Res. 115, 450-459
35. Khallou-Laschet, J. et al. (2010) Macrophage plasticity in experimental atherosclerosis. PLoS ONE 5, e8852
36. Feig, J.E. et al. (2012) Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS ONE 7, e39790
37. Pernow, J. and Jung, C. (2013) Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc. Res. 98, 334-343
38. Steppan, J. et al. (2013) Development of novel arginase inhibitors for therapy of endothelial dysfunction. Front. Immunol. 4, 278
39. Schneemann, M. and Schoeden, G. (2007) Macrophage biology and immunology: man is not a mouse. J. Leukoc. Biol. 81, 579
40. Mills, C.D. et al. (2014) Macrophage: SHIP of Immunity. Front. Immunol. 5, 620
41. Thomas, A.C. and Mattila, J.T. (2014) 'Of mice and men': arginine metabolism in macrophages. Front. Immunol. 5, 479
42. Jung, C. et al. (2010) Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc. Res. 85, 147-154
43. Gonon, A.T. et al. (2012) Local arginase inhibition during early reperfusion mediates cardioprotection via increased nitric oxide production. PLoS ONE 7, e42038
44. Gronros, J. et al. (2013) Arginase inhibition improves coronary microvascular function and reduces infarct size following ischaemia-reperfusion in a rat model. Acta Physiol. (Oxf.) 208, 172-179
45. Tratsiakovich, Y. et al. (2013) Arginase as a target for treatment of myocardial ischemia-reperfusion injury. Eur. J. Pharmacol. 720, 121-123
46. Shatanawi, A. et al. (2011) Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am. J. Physiol. Cell Physiol. 300, C1181-C1192
47. Chandra, S. et al. (2012) Oxidative species increase arginase activity in endothelial cells through RhoA/Rho kinase pathway. Br. J. Pharmacol. 165, 506-519
48. Wang, L. et al. (2014) Arginase inhibition enhances angiogenesis in endothelial cells exposed to hypoxia. Microvasc. Res. 98C, 1-8
49. Berkowitz, D.E. et al. (2003) Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108, 2000-2006
50. Kim, J.H. et al. (2009) Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J. Appl. Physiol. 107, 1249-1257
51. Scalera, F. et al. (2009) Paradoxical effect of L-arginine: acceleration of endothelial cell senescence. Biochem. Biophys. Res. Commun. 386, 650-655
52. Yepuri, G. et al. (2012) Positive crosstalk between arginase-II and S6K1 in vascular endothelial inflammation and aging. Aging Cell 11, 1005-1016
53. Xiong, Y. et al. (2013) Arginase-II induces vascular smooth muscle cell senescence and apoptosis through p66Shc and p53 independently of its l-arginine ureahydrolase activity: implications for atherosclerotic plaque vulnerability. J. Am. Heart Assoc. 2, e000096
54. Dean, R.C. and Lue, T.F. (2005) Physiology of penile erection and pathophysiology of erectile dysfunction. Urol. Clin. North Am. 32, 379-395
55. Toda, N. et al. (2005) Nitric oxide and penile erectile function. Pharmacol. Ther. 106, 233-266
56. Bivalacqua, T.J. et al. (2001) Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem. Biophys. Res. Commun. 283, 923-927
57. Cox, J.D. et al. (1999) Arginase-boronic acid complex highlights a physiological role in erectile function. Nat. Struct. Biol. 6, 1043-1047
58. Fraga-Silva, R.A. et al. (2014) An increased arginase activity is associated with corpus cavernosum impairment induced by hypercholesterolemia. J. Sex Med. 11, 1173-1181
59. Segal, R. et al. (2012) Chronic oral administration of the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) improves erectile function in aged rats. J. Androl. 33, 1169-1175
60. Toque, H.A. et al. (2011) Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. J. Sex Med. 8, 722-733
61. Ma, T.C. et al. (2010) A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway. J. Neurosci. 30, 739-748
62. Deng, K. et al. (2009) Increased synthesis of spermidine as a result of upregulation of arginase I promotes axonal regeneration in culture and in vivo. J. Neurosci. 29, 9545-9552
63. Peters, D. et al. (2013) Arginase and arginine decarboxylase - where do the putative gate keepers of polyamine synthesis reside in rat brain? PLoS ONE 8, e66735
64. Patel, C. et al. (2013) Arginase as a mediator of diabetic retinopathy. Front. Immunol. 4, 173
65. Zhang, W. et al. (2009) Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am. J. Pathol. 175, 891-902
66. Narayanan, S.P. et al. (2011) Arginase 2 deletion reduces neuro-glial injury and improves retinal function in a model of retinopathy of prematurity. PLoS ONE 6, e22460
67. Narayanan, S.P. et al. (2014) Arginase 2 deficiency reduces hyperoxiamediated retinal neurodegeneration through the regulation of polyamine metabolism. Cell Death Dis. 5, e1075
68. Toda, N. et al. (2009) Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol. Rev. 61, 62-97
69. Garry, P.S. et al. (2015) The role of the nitric oxide pathway in brain injury and its treatment - from bench to bedside. Exp. Neurol. 263C, 235-243
70. Quirie, A. et al. (2013) Effect of stroke on arginase expression and localization in the rat brain. Eur. J. Neurosci. 37, 1193-1202
71. Colton, C.A. et al. (2006) Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflamm. 3, 27
72. Hansmannel, F. et al. (2010) Is the urea cycle involved in Alzheimer's disease? J. Alzheimers Dis. 21, 1013-1021
73. Liu, P. et al. (2014) Altered arginine metabolism in Alzheimer's disease brains. Neurobiol. Aging 35, 1992-2003
74. Cherian, L. et al. (2004) Nitric oxide in traumatic brain injury. Brain Pathol. 14, 195-201
75. Cherian, L. and Robertson, C.S. (2003) L-arginine and free radical scavengers increase cerebral blood flow and brain tissue nitric oxide concentrations after controlled cortical impact injury in rats. J. Neurotrauma 20, 77-85
76. Bitner, B.R. et al. (2010) Impact of arginase II on CBF in experimental cortical impact injury in mice using MRI. J. Cereb. Blood Flow Metab. 30, 1105-1109
77. Zahedi, K. et al. (2010) Polyamine catabolism is enhanced after traumatic brain injury. J. Neurotrauma 27, 515-525
78. Rosi, S. et al. (2012) The polyamine inhibitor alpha-difluoromethylornithine modulates hippocampus-dependent function after single and combined injuries. PLoS ONE 7, e31094
79. Walter, S.D. et al. (2012) Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology 119, 1250-1257
80. Sakai, R.E. et al. (2011) Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J. Neuroophthalmol. 31, 362-373
81. Ljubisavljevic, S. et al. (2012) Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis. J. Neurol. Sci. 318, 106-111
82. Ljubisavljevic, S. et al. (2014) The importance of nitric oxide and arginase in the pathogenesis of acute neuroinflammation: are those contra players with the same direction? Neurotox Res. 26, 392-399
83. -/- mice in ischemic retinopathy. Invest. Ophthalmol. Vis. Sci. 51, 3291-3299
84. Brooks, S.E. et al. (2001) Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest. Ophthalmol. Vis. Sci. 42, 222-228
85. Gu, X. et al. (2002) Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 43, 496-502
86. Sennlaub, F. et al. (2001) Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J. Clin. Invest. 107, 717-725
87. Suwanpradid, J. et al. (2014) Arginase 2 deficiency prevents oxidative stress and limits hyperoxia-induced retinal vascular degeneration. PLoS ONE 9, e110604
88. Davoodi, J. et al. (1998) Overexpression and characterization of the human mitochondrial and cytosolic branched-chain aminotransferases. J. Biol. Chem. 273, 4982-4989
89. Huynh, N.N. et al. (2009) The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br. J. Pharmacol. 156, 84-93
90. Hunter, A. and Downs, D. (1945) The inhibition of arginase by amino acids. J. Biol. Chem. 157, 427-446
91. Shearer, J.D. et al. (1997) Differential regulation of macrophage arginine metabolism: a proposed role in wound healing. Am. J. Physiol. 272, E181-E190
92. Kanyo, Z.F. et al. (1996) Structure of a unique binuclear manganese cluster in arginase. Nature 383, 554-557
93. Di Costanzo, L. et al. (2005) Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proc. Natl. Acad. Sci. U.S.A. 102, 13058-13063
94. Ryoo, S. et al. (2008) Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ. Res. 102, 923-932
95. Yang, M. et al. (2006) Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J. Immunol. 177, 5595-5603
96. Bivalacqua, T.J. et al. (2007) Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase. Am. J. Physiol. Heart Circ. Physiol. 292, H1340-H1351
97. Kovamees, O. et al. (2014) Effect of arginase inhibition on ischemia-reperfusion injury in patients with coronary artery disease with and without diabetes mellitus. PLoS ONE 9, e103260
98. Quitter, F. et al. (2013) Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion. Clin. Hemorheol. Microcirc. 54, 75-85
99. Holowatz, L.A. and Kenney, W.L. (2007) Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans. J. Physiol. 581, 863-872
100. Jung, C. et al. (2014) Increased arginase levels contribute to impaired perfusion after cardiopulmonary resuscitation. Eur. J. Clin. Invest. 44, 965-971
101. Satriano, J. (2004) Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines: review article. Amino Acids 26, 321-329
102. Lange, P.S. et al. (2004) Novel roles for arginase in cell survival, regeneration, and translation in the central nervous system. J. Nutr. 134, 2812S-2817S
103. Witte, M.B. and Barbul, A. (2003) Arginine physiology and its implication for wound healing. Wound Repair Regen. 11, 419-423
104. Osowska, S. et al. (2004) Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection. Gut 53, 1781-1786
105. Deignan, J.L. et al. (2008) Contrasting features of urea cycle disorders in human patients and knockout mouse models. Mol. Genet. Metab. 93, 7-14
106. Huynh, N.N. et al. (2009) Arginase II knockout mouse displays a hypertensive phenotype despite a decreased vasoconstrictory profile. Hypertension 54, 294-301
107. Kampfer, H. et al. (2003) Expression and activity of arginase isoenzymes during normal and diabetes-impaired skin repair. J. Invest. Dermatol. 121, 1544-1551
108. Esch, F. et al. (1998) Purification of a multipotent antideath activity from bovine liver and its identification as arginase: nitric oxide-independent inhibition of neuronal apoptosis. J. Neurosci. 18, 4083-4095
109. Filbin, M.T. (1996) The muddle with MAG. Mol. Cell. Neurosci. 8, 84-92
110. Kuo, H.S. et al. (2007) The combination of peripheral nerve grafts and acidic fibroblast growth factor enhances arginase I and polyamine spermine expression in transected rat spinal cords. Biochem. Biophys. Res. Commun. 357, 1-7
111. Narayanan, S.P. et al. (2013) Arginase in retinopathy. Prog. Retin Eye Res. 36, 260-280
112. Durante, W. (2013) Role of arginase in vessel wall remodeling. Front. Immunol. 4, 111
113. Yang, Z. and Ming, X.F. (2014) Functions of arginase isoforms in macrophage inflammatory responses: impact on cardiovascular diseases and metabolic disorders. Front. Immunol. 5, 533
114. Hein, T.W. et al. (2003) Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 17, 2328-2330
115. Johnson, F.K. et al. (2005) Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R1057-R1062
116. Zhang, C. et al. (2004) Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44, 935-943
117. Wood, P.L. et al. (2006) Neurotoxicity of reactive aldehydes: the concept of 'aldehyde load' as demonstrated by neuroprotection with hydroxylamines. Brain Res. 1095, 190-199
118. Takano, K. et al. (2005) Neuronal and glial responses to polyamines in the ischemic brain. Curr. Neurovasc. Res. 2, 213-223
119. Ivanova, S. et al. (2002) Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal. Proc. Natl. Acad. Sci. U.S.A. 99, 5579-5584
120. Seiler, N. (2000) Oxidation of polyamines and brain injury. Neurochem. Res. 25, 471-490
121. Munder, M. (2009) Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol. 158, 638-651
122. Furchgott, R.F. and Vanhoutte, P.M. (1989) Endothelium-derived relaxing and contracting factors. FASEB J. 3, 2007-2018
123. Bryan, N.S. et al. (2009) Discovery of the nitric oxide signaling pathway and targets for drug development. Front. Biosci. 14, 1-18
124. Forstermann, U. and Sessa, W.C. (2012) Nitric oxide synthases: regulation and function. Eur. Heart J. 33, 829-837 837a-837d
125. McDonald, K.K. et al. (1997) A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the 'arginine paradox'. J. Biol. Chem. 272, 31213-31216
126. De Caterina, R. et al. (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96, 60-68
127. Kubes, P. et al. (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U.S.A. 88, 4651-4655
128. Radomski, M.W. et al. (1987) Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2, 1057-1058
129. Murad, F. (1999) Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Biosci. Rep. 19, 133-154
130. Pacher, P. et al. (2007) Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315-424